Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
July 22 2024 - 2:00AM
Strasbourg, France, and Lund, Sweden, July 22,
2024, 8:00 a.m. CET – Transgene (Euronext Paris:
TNG), a biotech company that designs and develops
virus-based immunotherapies for the treatment of cancer, and
BioInvent International AB (“BioInvent”)
(Nasdaq Stockholm: BINV), a biotech company focused on the
discovery and development of novel and first-in-class
immune-modulatory antibodies for cancer immunotherapy, will
jointly present a poster on initial clinical results from the Phase
I part of the ongoing randomized Phase I/IIa trial of BT-001 at the
European Society of Medical Oncology (ESMO) Annual
Meeting. ESMO will take place in Barcelona, Spain, from September
13 to 17, 2024.
Poster and abstract title: “Initial
clinical results of BT-001, an oncolytic virus expressing an
anti-CTLA4 mAb, administered as single agent and in combination
with pembrolizumab in patients with advanced solid
tumors.”
- Presentation topic: Investigational immunotherapy
- Presentation number: 1024P
- Speaker: Stéphane Champiat
The abstract will be available on ESMO’s website
on September 9, 2024, at 0:05 a.m. CEST.
BT-001 is an oncolytic virus generated using
Transgene’s Invir.IO® platform and its patented large-capacity
VVcopTK-RR- oncolytic virus, which has been engineered to encode
both a Treg-depleting recombinant human anti-CTLA-4 antibody
generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T™ platforms,
and the human GM-CSF cytokine.
BT-001 is expected to induce a much stronger and
more effective antitumoral response by selectively targeting the
tumor microenvironment, thereby potentially enhancing the safety
and tolerability profile of the anti-CTLA-4 antibody through
reduced systemic exposure.
The ongoing Phase I/IIa study (NCT04725331) is a
multicenter, open label, dose-escalation trial evaluating BT-001 as
a single agent and in combination with pembrolizumab (anti-PD-1
treatment). Patient inclusions are ongoing in Europe (France,
Belgium) and the trial has been authorized in the US.
***
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of
a portfolio of therapeutic vaccines and oncolytic viruses: TG4050,
the first individualized therapeutic vaccine based on the myvac®
platform, TG4001 for the treatment of HPV-positive cancers, as well
as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO®
viral backbone. With Transgene’s myvac® platform, therapeutic
vaccination enters the field of precision medicine with a novel
immunotherapy that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO®, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.frFollow us on social
media: X (previously-Twitter): @TransgeneSA - LinkedIn:
@Transgene
About BioInventBioInvent
International AB (Nasdaq Stockholm: BINV) is a clinical-stage
biotech company that discovers and develops novel and
first-in-class immuno-modulatory antibodies for cancer therapy,
with currently four drug candidates in five ongoing clinical
programs in Phase 1/2 trials for the treatment of hematological
cancer and solid tumors, respectively. The Company’s validated,
proprietary F.I.R.S.T.™ technology platform identifies both targets
and the antibodies that bind to them, generating many promising new
drug candidates to fuel the Company’s own clinical development
pipeline and providing licensing and partnering opportunities.The
Company generates revenues from research collaborations and license
agreements with multiple top-tier pharmaceutical companies, as well
as from producing antibodies for third parties in the Company’s
fully integrated manufacturing unit. More information is available
at www.bioinvent.com. Follow on Twitter: @BioInvent.More
information is available at www.bioinvent.com.Follow us on
Twitter: @BioInvent
Contacts
Transgene
Contact:Media:Caroline
ToschCorporate Communication
Manager+33 3 68 33 27 38communication@transgene.fr Investor:Nadege
BartoliIR Analyst and Financial Communications Officer+33
3 88 27 91 03Lucie LarguierChief Financial
Officer +33 3 88 27 91 00investorrelations@transgene.fr |
Transgene
Media Contact:MEDiSTRAVA Frazer
Hall/Sylvie Berrebi+ 44
(0)203 928 6900transgene@medistrava.com |
BioInvent :Cecilia
HofvanderSenior Director Investor Relations+46 (0) 46 286
85 50cecilia.hofvander@bioinvent.com
Transgene disclaimer
This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the
future.
BioInvent disclaimer
The press release contains statements about the
future, consisting of subjective assumptions and forecasts for
future scenarios. Predictions for the future only apply as the date
they are made and are, by their very nature, in the same way as
research and development work in the biotech segment, associated
with risk and uncertainty. With this in mind, the actual outcome
may deviate significantly from the scenarios described in this
press release.
- 20240722_Transgene_ESMO_curtain_Raiser_BT001_EN
Transgene (EU:TNG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Transgene (EU:TNG)
Historical Stock Chart
From Aug 2023 to Aug 2024